FI20021798A - Peptidit jotka moduloivat kaspaasin aktivoitumisen - Google Patents
Peptidit jotka moduloivat kaspaasin aktivoitumisenInfo
- Publication number
- FI20021798A FI20021798A FI20021798A FI20021798A FI20021798A FI 20021798 A FI20021798 A FI 20021798A FI 20021798 A FI20021798 A FI 20021798A FI 20021798 A FI20021798 A FI 20021798A FI 20021798 A FI20021798 A FI 20021798A
- Authority
- FI
- Finland
- Prior art keywords
- peptides
- asp
- structures
- fetoprotein
- sequences
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 abstract 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 3
- 102100027211 Albumin Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100030497 Cytochrome c Human genes 0.000 abstract 1
- 108010075031 Cytochromes c Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 230000005775 apoptotic pathway Effects 0.000 abstract 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20021798A FI118263B (fi) | 2002-10-09 | 2002-10-09 | Kaspaasiaktiivisuutta säätelevät peptidit |
| EP03753618A EP1558649B1 (en) | 2002-10-09 | 2003-10-07 | Peptid modulating caspase activation |
| CNB2003801011658A CN100551930C (zh) | 2002-10-09 | 2003-10-07 | 调节caspase活化的肽 |
| AT03753618T ATE470677T1 (de) | 2002-10-09 | 2003-10-07 | Peptid zur modulation der caspase-aktivierung |
| JP2004542524A JP4446121B2 (ja) | 2002-10-09 | 2003-10-07 | カスパーゼ活性化調節ペプチド |
| EA200500606A EA010058B1 (ru) | 2002-10-09 | 2003-10-07 | Пептиды, модулирующие активацию каспазы |
| PT03753618T PT1558649E (pt) | 2002-10-09 | 2003-10-07 | Péptidos que modulam a activação de caspases |
| PCT/FI2003/000735 WO2004033500A1 (en) | 2002-10-09 | 2003-10-07 | Peptides modulating caspase activation |
| DK03753618.2T DK1558649T3 (da) | 2002-10-09 | 2003-10-07 | Peptid til modulering af caspaseaktivering |
| DE60332950T DE60332950D1 (de) | 2002-10-09 | 2003-10-07 | Peptid zur modulation der caspase-aktivierung |
| AU2003271784A AU2003271784A1 (en) | 2002-10-09 | 2003-10-07 | Peptides modulating caspase activation |
| ES03753618T ES2347234T3 (es) | 2002-10-09 | 2003-10-07 | Peptido modulador de la activacion de caspasa. |
| US10/530,779 US7446095B2 (en) | 2002-10-09 | 2003-10-07 | Peptides modulating caspase activation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20021798A FI118263B (fi) | 2002-10-09 | 2002-10-09 | Kaspaasiaktiivisuutta säätelevät peptidit |
| FI20021798 | 2002-10-09 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20021798A0 FI20021798A0 (fi) | 2002-10-09 |
| FI20021798A true FI20021798A (fi) | 2004-04-10 |
| FI118263B FI118263B (fi) | 2007-09-14 |
Family
ID=8564726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20021798A FI118263B (fi) | 2002-10-09 | 2002-10-09 | Kaspaasiaktiivisuutta säätelevät peptidit |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7446095B2 (fi) |
| EP (1) | EP1558649B1 (fi) |
| JP (1) | JP4446121B2 (fi) |
| CN (1) | CN100551930C (fi) |
| AT (1) | ATE470677T1 (fi) |
| AU (1) | AU2003271784A1 (fi) |
| DE (1) | DE60332950D1 (fi) |
| DK (1) | DK1558649T3 (fi) |
| EA (1) | EA010058B1 (fi) |
| ES (1) | ES2347234T3 (fi) |
| FI (1) | FI118263B (fi) |
| PT (1) | PT1558649E (fi) |
| WO (1) | WO2004033500A1 (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2444105A4 (en) * | 2009-06-16 | 2013-08-21 | Univ Tokai | GRAM NEGATIVE ANTI-BACTERIAL AGENT |
| CN101812448B (zh) * | 2010-01-15 | 2011-12-07 | 浙江大学 | 一种肝癌靶向双重组凋亡蛋白表达序列及应用 |
| CN102060913B (zh) * | 2010-11-30 | 2012-09-05 | 暨南大学 | 一种与人血清白蛋白结合的七肽与应用 |
| US10238690B2 (en) | 2013-03-15 | 2019-03-26 | Celgene Corporation | Modified T lymphocytes comprising an inducible caspase and methods of apoptosis |
| CN108186666B (zh) * | 2018-01-29 | 2020-02-21 | 西北大学 | 一种dna纳米带在抗细胞凋亡上的应用及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226551B (it) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico |
| EP0805687A4 (en) | 1995-01-24 | 2000-05-31 | Robert A Murgita | ALPHA-F RECOMBINANT HUMAN TOPROTEIN AND USES THEREOF |
| WO1998010792A1 (en) * | 1996-09-11 | 1998-03-19 | Prendergast Patrick T | Immune direction therapy |
| CN1739791A (zh) * | 1997-02-13 | 2006-03-01 | 加利福尼亚大学董事会 | 肝细胞癌的预防及治疗 |
| AU7104500A (en) * | 1999-09-02 | 2001-03-26 | Atlantic Biopharmaceuticals, Inc. | Use of rafp to inhibit or prevent apoptosis |
| ATE494301T1 (de) * | 2001-06-02 | 2011-01-15 | Clf Medical Technology Acceleration Program Inc | Alpha-fetoprotein-peptide und ihre verwendung |
-
2002
- 2002-10-09 FI FI20021798A patent/FI118263B/fi active IP Right Grant
-
2003
- 2003-10-07 AU AU2003271784A patent/AU2003271784A1/en not_active Abandoned
- 2003-10-07 AT AT03753618T patent/ATE470677T1/de active
- 2003-10-07 ES ES03753618T patent/ES2347234T3/es not_active Expired - Lifetime
- 2003-10-07 PT PT03753618T patent/PT1558649E/pt unknown
- 2003-10-07 JP JP2004542524A patent/JP4446121B2/ja not_active Expired - Fee Related
- 2003-10-07 EP EP03753618A patent/EP1558649B1/en not_active Expired - Lifetime
- 2003-10-07 EA EA200500606A patent/EA010058B1/ru not_active IP Right Cessation
- 2003-10-07 US US10/530,779 patent/US7446095B2/en not_active Expired - Fee Related
- 2003-10-07 DE DE60332950T patent/DE60332950D1/de not_active Expired - Lifetime
- 2003-10-07 CN CNB2003801011658A patent/CN100551930C/zh not_active Expired - Fee Related
- 2003-10-07 DK DK03753618.2T patent/DK1558649T3/da active
- 2003-10-07 WO PCT/FI2003/000735 patent/WO2004033500A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| FI118263B (fi) | 2007-09-14 |
| DK1558649T3 (da) | 2010-10-11 |
| ES2347234T3 (es) | 2010-10-27 |
| EA010058B1 (ru) | 2008-06-30 |
| CN1703428A (zh) | 2005-11-30 |
| CN100551930C (zh) | 2009-10-21 |
| WO2004033500A1 (en) | 2004-04-22 |
| US7446095B2 (en) | 2008-11-04 |
| PT1558649E (pt) | 2010-09-14 |
| ATE470677T1 (de) | 2010-06-15 |
| AU2003271784A1 (en) | 2004-05-04 |
| JP2006518703A (ja) | 2006-08-17 |
| EP1558649A1 (en) | 2005-08-03 |
| EP1558649B1 (en) | 2010-06-09 |
| EA200500606A1 (ru) | 2006-06-30 |
| US20060280732A1 (en) | 2006-12-14 |
| DE60332950D1 (de) | 2010-07-22 |
| JP4446121B2 (ja) | 2010-04-07 |
| FI20021798A0 (fi) | 2002-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Enzymatic cleavage of branched peptides for targeting mitochondria | |
| CY1121767T1 (el) | Πολυπεπτιδια που περιεχουν μη γαυκοζυλιωμενη fc | |
| AR073829A1 (es) | Variantes de inmunoglobulinas y sus usos. | |
| BRPI0509879A (pt) | compostos para inibição enzimática | |
| Buckton et al. | Improving the cell permeability of polar cyclic peptides by replacing residues with alkylated amino acids, asparagines, and d-amino acids | |
| DE69925909D1 (de) | T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung | |
| LTPA2016010I1 (lt) | Junginiai, skirti proteasomos fermentų slopinimui | |
| WO2006102170A3 (en) | Recombinant mhc molecules useful for manipulation of antigen-specific t cells | |
| AR072596A1 (es) | Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico | |
| ES2181006T3 (es) | Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion. | |
| EA200601738A1 (ru) | Модифицированные белки буганины, цитотоксины и способы их применения | |
| TR199700610A2 (xx) | D���k molek�l a��rl�kl� ��z�n�r, t�m�r nekroz fakt�r� tip-I ve tip-II proteinleri. | |
| AR093641A1 (es) | Eliminacion de celulas de cancer por celulas t citotoxicas circulantes especificas de virus utilizando proteinas multifuncion que comprenden cmh de clase i con diana en celulas de cancer | |
| FI20021798A (fi) | Peptidit jotka moduloivat kaspaasin aktivoitumisen | |
| ATE494360T1 (de) | Neue zellpopulationen und deren anwendungen | |
| WO2018120843A9 (zh) | 一种三功能分子及其应用 | |
| RU2011110711A (ru) | Новые биологически активные пептиды и их новое применение | |
| Kuncewicz et al. | BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation–design, synthesis and biological evaluation | |
| EA201291416A1 (ru) | Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1 | |
| HRP20040663B1 (hr) | Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora | |
| ATE518263T1 (de) | Brennstoffzellen-reaktionsmittel-strömungsfelde zur maximierung der planform-ausnutzung | |
| BR0108187A (pt) | Moléculas trade e usos relacionados com as mesmas | |
| AR112770A1 (es) | Anticuerpos anti-ctla-4 y sus usos | |
| WO2003104262A3 (en) | GP41 PEPTIDES AND METHODS USING SUCH PEPTIDES TO INHIBIT HIV FUSION WITH TARGET CELLS | |
| WO2023183413A3 (en) | Transferrin-based lysosome targeting degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118263 Country of ref document: FI |